Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmad Awada

Showing results (11-20 of 311) with videos related to

Pageof 32
Sort By:
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer|May 16, 2024
MONARCH-plus: the evidence of efficacy and safety of abemaciclib in countries with limited clinical research opportunitiesAhmad Awada, Andrea Gombos
Current Opinion in Oncology|April 9, 2005
Molecular markers, molecular-targeted therapies and taxanes: how to integrate the progress into clinical research and practice for the management of head and neck cancersAhmad Awada, Yassine Lalami
Bulletin Du Cancer|April 24, 2008
Oncology in Belgium: a global approach where research and clinic are joiningAhmad Awada, Guy Storme
Critical Reviews in Oncology/Hematology|March 5, 2025
Molecular oncology of iodine refractory thyroid cancer current therapies and perspectiveFrançois Cherifi, Ahmad Awada
Critical Reviews in Oncology/Hematology|March 16, 2010
Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?Jean Klastersky, Ahmad Awada
Current Opinion in Oncology|April 7, 2007
The challenging integration of platinum compounds, taxanes, and molecular-targeted therapies in the multidisciplinary treatment of squamous cell carcinoma of the head and neckAhmad Awada, Gustavo Ismael
Current Opinion in Oncology|March 16, 2013
Targeted therapies of solid cancers: new options, new challengesAhmad Awada, Philippe G Aftimos
Current Opinion in Oncology|May 25, 2006
Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies)Gilberto de Castro, Ahmad Awada
Cancer Chemotherapy and Pharmacology|November 21, 2007
Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trialsChris H Takimoto, Ahmad Awada
Current Opinion in Oncology|February 21, 2012
Clinical development of new formulations of cytotoxics in solid tumorsHatem A Azim, Ahmad Awada
Pageof 32

Showing results (11-20 of 311) with videos related to

Sort By:
Pageof 32
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer|May 16, 2024
MONARCH-plus: the evidence of efficacy and safety of abemaciclib in countries with limited clinical research opportunitiesAhmad Awada, Andrea Gombos
Current Opinion in Oncology|April 9, 2005
Molecular markers, molecular-targeted therapies and taxanes: how to integrate the progress into clinical research and practice for the management of head and neck cancersAhmad Awada, Yassine Lalami
Bulletin Du Cancer|April 24, 2008
Oncology in Belgium: a global approach where research and clinic are joiningAhmad Awada, Guy Storme
Critical Reviews in Oncology/Hematology|March 5, 2025
Molecular oncology of iodine refractory thyroid cancer current therapies and perspectiveFrançois Cherifi, Ahmad Awada
Critical Reviews in Oncology/Hematology|March 16, 2010
Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?Jean Klastersky, Ahmad Awada
Current Opinion in Oncology|April 7, 2007
The challenging integration of platinum compounds, taxanes, and molecular-targeted therapies in the multidisciplinary treatment of squamous cell carcinoma of the head and neckAhmad Awada, Gustavo Ismael
Current Opinion in Oncology|March 16, 2013
Targeted therapies of solid cancers: new options, new challengesAhmad Awada, Philippe G Aftimos
Current Opinion in Oncology|May 25, 2006
Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies)Gilberto de Castro, Ahmad Awada
Cancer Chemotherapy and Pharmacology|November 21, 2007
Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trialsChris H Takimoto, Ahmad Awada
Current Opinion in Oncology|February 21, 2012
Clinical development of new formulations of cytotoxics in solid tumorsHatem A Azim, Ahmad Awada
Pageof 32